• By ICR Secretariat
  • Posted Wednesday, March 27, 2019

Aimmune's peanut allergy drug finally gets an approval timeline


A peanut allergy drug developed by Aimmune Therapeutics has finally been accepted for review by the Food and Drug Administration, after delays caused by the 35-day U.S. government shutdown temporarily derailed the company's application.